Phase I study of the novel oral steroidal antiestrogenic agent TAS-108, ascending single dose, safety, tolerance, and pharmacokinetic parameters in healthy postmenopausal women.

被引：0
|
作者：
Kuritani, J
Abdelhameed, M
Boyeson, M
Dixon, RM
Pfefferkorn, C
Yonezawa, J
Shindo, T
Minami, Y
Buzdar, AU
机构：
[1] Taiho Pharmaceut Co Ltd, Tokyo, Japan
[2] Covance Clin Res Unit Inc, Madison, WI USA
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
456
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [41] A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects
    Michael J. Fossler
    Virginia Schmith
    Stephen A. Greene
    Lauren Lohmer
    Michael S. Kramer
    Kelly Arscott
    Ian E. James
    Mark A. Demitrack
    CNS Drugs, 2020, 34 : 853 - 865
  • [42] A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects
    Brager, Jenna
    Chapman, Chris
    Dunn, Leonard
    Kaplin, Adam
    DRUG RESEARCH, 2023, 73 (02) : 95 - 104
  • [43] Pharmacokinetic, Pharmacodynamic, and Safety/Tolerability Profiles of CG100649, a Novel COX-2 Inhibitor: Results of a Phase I, Randomized, Multiple-dose Study in Healthy Korean Men and Women
    Kim, Mi Jo
    Lim, Hyeong-Seok
    Jin, Seokjoon
    Jung, Jin Ah
    Noh, Yook-Hwan
    Kim, Yo Han
    Bae, Kyun-Seop
    CLINICAL THERAPEUTICS, 2015, 37 (01) : 197 - 210
  • [44] Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects
    Wang, LH
    Peck, RW
    Yin, Y
    Allanson, J
    Wiggs, R
    Wire, MB
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) : 1334 - 1342
  • [45] A Phase I, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
    Liu, Chao
    Lu, Hong
    Yuan, Fei
    Chen, Wei-Li
    Xu, Hong-Rong
    Li, Hui
    Hsu, Cheng-Pang
    Egbuna, Ogo
    Wu, Jihua
    Dias, Clapton
    Abosaleem, Bassam
    Rana, Jitesh
    Monsalvo, Maria Laura
    Li, Xue-Ning
    Yu, Zhigang
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2019, 11 : 145 - 153
  • [46] A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers
    Liu, Jingrui
    Lv, Binhua
    Yin, Hewen
    Zhu, Xiaoxue
    Wei, Haijing
    Ding, Yanhua
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [47] A Phase I, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects
    Fossler, Michael J.
    Schmith, Virginia
    Greene, Stephen A.
    Lohmer, Lauren
    Kramer, Michael S.
    Arscott, Kelly
    James, Ian E.
    Demitrack, Mark A.
    CNS DRUGS, 2020, 34 (08) : 853 - 865
  • [48] A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer
    Dowlati, A
    Robertson, K
    Cooney, M
    Petros, WP
    Stratford, M
    Jesberger, J
    Rafie, N
    Overmoyer, B
    Makkar, V
    Stambler, B
    Taylor, A
    Waas, J
    Lewin, JS
    McCrae, KR
    Remick, SC
    CANCER RESEARCH, 2002, 62 (12) : 3408 - 3416
  • [49] First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects
    Wang, Meng-na
    Kuang, Yun
    Gong, Li-ying
    Hua, Ye
    Pei, Qi
    Guo, Cheng-xian
    Cao, Yu
    Huang, Jie
    Yang, Guo-ping
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1826 - 1835
  • [50] Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants
    Dauki, Anees M.
    Rajakumaraswamy, Nishanthan
    Trowe, Torsten
    Weng, Winnie
    Lin, Kai-Wen
    Elboudjwarej, Emon
    Qin, Ann Ran-Ran
    Schwabe, Christian
    Kuhne, Michelle R.
    Othman, Ahmed A.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (08):
12345